Riociguat, a pioneering soluble guanylate cyclase (sGC) stimulator, is approved for treating pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) [13,14]. Here, SGCB is linked to pulmonary arterial hypertension.